Abcam, ab85799, Anti-Sclerostin antibody

Size: 100µg
Rabbit Polyclonal Sclerostin antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 11 publications.
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:From Mar 2024, QC testing of replenishment batches of this polyclonal changed. All tested and expected application and reactive species combinations are still covered by our Abcam product promise. However, we no longer test all applications. For more information on a specific batch, please contact our Scientific Support who will be happy to help.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Sclerostin also known as SOST is a glycoprotein weighing approximately 22 kDa. It is predominantly expressed in osteocytes the most abundant cells found in bone. Sclerostin is an extracellular molecule that plays a role in bone metabolism by inhibiting the Wnt signaling pathway which is important for bone formation. This protein acts as a negative regulator of bone growth by binding to the LRP5/6 receptors. Inhibitors such as 'anti-sclerostin' antibodies have been developed to block its function and promote bone formation.
Biological function summary
Sclerostin inhibits osteoblastic activity and formation by interfering with bone morphogenetic proteins. It doesn’t form part of a large protein complex but interacts directly with cell surface receptors. Its expression decreases in response to mechanical loading on bones which is an important part of regulating bone density and remodeling. By controlling osteoblast function sclerostin contributes to skeletal homeostasis an essential process for maintaining bone strength and integrity.
Pathways
Several mechanisms regulate sclerostin activity. In the canonical Wnt/β-catenin signaling pathway it serves as an important checkpoint that ensures controlled bone formation. Sclerostin acts by preventing the activation of LRP5/6 receptors pivotal components in this pathway. Additionally it shares a regulatory network with dickkopf-1 (DKK1) another Wnt inhibitor both of which have an influence on bone metabolism and development.
Two primary conditions associated with sclerostin are osteoporosis and sclerosteosis. Osteoporosis arises from excessive inhibition of bone formation and is characterized by fragile bones due to decreased bone mass. On the other hand sclerosteosis results from mutations in the SOST gene leading to excessive bone growth. Sclerostin's interaction with proteins like DKK1 clarifies its role in bone density management and highlights its relevance in therapeutic strategies targeting these conditions.